Literature DB >> 20495714

Validation of a prediction rule to maximize curative (R0) resection of early-stage pancreatic adenocarcinoma.

Philip Bao, Douglas Potter, David P Eisenberg, Diana Lenzner, Herbert J Zeh, Kenneth Kw Lee Iii, Steven J Hughes, Michael K Sanders, Jennifer L Young, A James Moser.   

Abstract

BACKGROUND: The surgeon's contribution to patients with localized pancreatic adenocarcinoma (PAC) is a margin negative (R0) resection. We hypothesized that a prediction rule based on pre-operative imaging would maximize the R0 resection rate while reducing non-therapeutic intervention.
METHODS: The prediction rule was developed using computed tomography (CT) and endoscopic ultrasound (EUS) data from 65 patients with biopsy-proven PAC who underwent attempted resection. The rule classified patients as low or high risk for non-R0 outcome and was validated in 78 subsequent patients.
RESULTS: MODEL VARIABLES WERE: any evidence of vascular involvement on CT; EUS stage and EUS size dichotomized at 2.6 cm. In the validation cohort, 77% underwent resection and 58% achieved R0 status. If only patients in the low-risk group underwent surgery, the prediction rule would have increased the resection rate to 92% and the R0 rate to 73%. The R0 rate was 40% higher in low-risk compared with high-risk patients (P < 0.001). High risk was associated with a 67% rate of non-curative surgery (unresectable disease and metastases).
CONCLUSION: The prediction rule identified patients most likely to benefit from resection for PAC using pre-operative CT and EUS findings. Model predictions would have increased the R0 rate and reduced non-therapeutic interventions.

Entities:  

Year:  2009        PMID: 20495714      PMCID: PMC2785957          DOI: 10.1111/j.1477-2574.2009.00110.x

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  14 in total

1.  Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer.

Authors:  Rebekah R White; H Bill Xie; Marcia R Gottfried; Brian G Czito; Herbert I Hurwitz; Michael A Morse; Gerald C Blobe; Erik K Paulson; John Baillie; M Stanley Branch; Paul S Jowell; Bryan M Clary; Theodore N Pappas; Douglas S Tyler
Journal:  Ann Surg Oncol       Date:  2005-03-03       Impact factor: 5.344

Review 2.  Computed tomography, endoscopic, laparoscopic, and intra-operative sonography for assessing resectability of pancreatic cancer.

Authors:  Eliza E Long; Jacques Van Dam; Stefanie Weinstein; Brooke Jeffrey; Terry Desser; Jeffrey A Norton
Journal:  Surg Oncol       Date:  2005-08       Impact factor: 3.279

Review 3.  Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy.

Authors:  Gauri R Varadhachary; Eric P Tamm; James L Abbruzzese; Henry Q Xiong; Christopher H Crane; Huamin Wang; Jeffrey E Lee; Peter W T Pisters; Douglas B Evans; Robert A Wolff
Journal:  Ann Surg Oncol       Date:  2006-07-24       Impact factor: 5.344

4.  Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas.

Authors:  Murray F Brennan; Michael W Kattan; David Klimstra; Kevin Conlon
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

5.  Preoperative staging and tumor resectability assessment of pancreatic cancer: prospective study comparing endoscopic ultrasonography, helical computed tomography, magnetic resonance imaging, and angiography.

Authors:  Antonio Soriano; Antoni Castells; Carmen Ayuso; Juan Ramón Ayuso; Maria Teresa de Caralt; Maria Angels Ginès; Maria Isabel Real; Rosa Gilabert; Llorenç Quintó; Antoni Trilla; Faust Feu; Xavier Montanyà; Laureano Fernández-Cruz; Salvador Navarro
Journal:  Am J Gastroenterol       Date:  2004-03       Impact factor: 10.864

6.  Predicting unresectability in pancreatic cancer patients: the additive effects of CT and endoscopic ultrasound.

Authors:  Susannah Yovino; Peter Darwin; Barry Daly; Michael Garofalo; Robert Moesinger
Journal:  J Gastrointest Surg       Date:  2007-01       Impact factor: 3.452

7.  Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head.

Authors:  Gauri R Varadhachary; Robert A Wolff; Christopher H Crane; Charlotte C Sun; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Eddie Abdalla; Huamin Wang; Gregg A Staerkel; Jeffrey H Lee; William A Ross; Eric P Tamm; Priya R Bhosale; Sunil Krishnan; Prajnan Das; Linus Ho; Henry Xiong; James L Abbruzzese; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-07-20       Impact factor: 44.544

8.  Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.

Authors:  Douglas B Evans; Gauri R Varadhachary; Christopher H Crane; Charlotte C Sun; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Huamin Wang; Karen R Cleary; Gregg A Staerkel; Chusilp Charnsangavej; Elizabeth A Lano; Linus Ho; Renato Lenzi; James L Abbruzzese; Robert A Wolff
Journal:  J Clin Oncol       Date:  2008-07-20       Impact factor: 44.544

9.  Clinical utility of endoscopic ultrasound in solid pancreatic mass lesions deemed resectable by computer tomography.

Authors:  Mark A Virtue; Shawn Mallery; Rebecca Li; Timothy D Sielaff
Journal:  JOP       Date:  2008-03-08

10.  Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer.

Authors:  John DeWitt; Benedict Devereaux; Melissa Chriswell; Kathleen McGreevy; Thomas Howard; Thomas F Imperiale; Donato Ciaccia; Kathleen A Lane; Dean Maglinte; Kenyon Kopecky; Julia LeBlanc; Lee McHenry; James Madura; Alex Aisen; Harvey Cramer; Oscar Cummings; Stuart Sherman
Journal:  Ann Intern Med       Date:  2004-11-16       Impact factor: 25.391

View more
  8 in total

1.  Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma.

Authors:  Brian A Boone; Nathan Bahary; Amer H Zureikat; A James Moser; Daniel P Normolle; Wen-Chi Wu; Aatur D Singhi; Phillip Bao; David L Bartlett; Lance A Liotta; Virginia Espina; Patricia Loughran; Michael T Lotze; Herbert J Zeh
Journal:  Ann Surg Oncol       Date:  2015-04-24       Impact factor: 5.344

2.  Hospital and medical care days in pancreatic cancer.

Authors:  Casey A Boyd; Daniel W Branch; Kristin M Sheffield; Yimei Han; Yong-Fang Kuo; James S Goodwin; Taylor S Riall
Journal:  Ann Surg Oncol       Date:  2012-03-27       Impact factor: 5.344

3.  Can laparoscopic pancreaticoduodenectomy be safely implemented?

Authors:  Amer H Zureikat; Jason A Breaux; Jennifer L Steel; Steven J Hughes
Journal:  J Gastrointest Surg       Date:  2011-05-03       Impact factor: 3.452

Review 4.  Neoadjuvant therapy for resectable pancreatic cancer.

Authors:  Sheikh Hasibur Rahman; Robin Urquhart; Michele Molinari
Journal:  World J Gastrointest Oncol       Date:  2017-12-15

Review 5.  Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer.

Authors:  E Versteijne; J A Vogel; M G Besselink; O R C Busch; J W Wilmink; J G Daams; C H J van Eijck; B Groot Koerkamp; C R N Rasch; G van Tienhoven
Journal:  Br J Surg       Date:  2018-04-30       Impact factor: 6.939

Review 6.  Encouraging long-term survival following autophagy inhibition using neoadjuvant hydroxychloroquine and gemcitabine for high-risk patients with resectable pancreatic carcinoma.

Authors:  Samer S AlMasri; Mazen S Zenati; Annissa Desilva; Ibrahim Nassour; Brian A Boone; Aatur D Singhi; David L Bartlett; Lance A Liotta; Virginia Espina; Patricia Loughran; Michael T Lotze; Alessandro Paniccia; Herbert J Zeh; Amer H Zureikat; Nathan Bahary
Journal:  Cancer Med       Date:  2021-09-24       Impact factor: 4.452

7.  A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients.

Authors:  Herbert J Zeh; Nathan Bahary; Brian A Boone; Aatur D Singhi; Jennifer Lee Miller-Ocuin; Daniel P Normolle; Amer H Zureikat; Melissa E Hogg; David L Bartlett; Kenneth K Lee; Allan Tsung; J Wallis Marsh; Pranav Murthy; Daolin Tang; Natalie Seiser; Ravi K Amaravadi; Virginia Espina; Lance Liotta; Michael T Lotze
Journal:  Clin Cancer Res       Date:  2020-03-10       Impact factor: 12.531

8.  Dramatic Survival Benefit Related to R0 Resection of Pancreatic Adenocarcinoma in Patients With Tumor ≤25 mm in Size and ≤1 Involved Lymph Nodes.

Authors:  Pavan Tummala; Todd Howard; Banke Agarwal
Journal:  Clin Transl Gastroenterol       Date:  2013-03-21       Impact factor: 4.488

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.